BridgeBio Pharma (BBIO) FCF Margin (2019 - 2026)
BridgeBio Pharma recorded quarterly FCF Margin of 101.46% in Q1 2026, down 172.02% quarter-over-quarter from 37.3% in Q4 2025, and up 6965.0% year-over-year from 1.44% in Q1 2025.
BridgeBio Pharma's FCF Margin history runs 8 years deep, the most recent figure standing at 101.46% for Q1 2026.
- In Q1 2026, FCF Margin rose 6965.0% year-over-year to 101.46%; the TTM figure through Mar 2026 stood at 76.69% (up 31700.0% YoY), while the FY2025 annual figure was 89.03%, up 14605.0% from the prior year.
- FCF Margin came in at 101.46% for Q1 2026 at BridgeBio Pharma, down from 37.3% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 3445.71% in Q2 2024 to a low of 39985.21% in Q3 2022.
- A 5-year average of 5129.51% and a median of 3321.54% in 2024 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin plunged 3452348 bps in 2022 and soared 3641723 bps in 2023, its largest moves.
- BridgeBio Pharma's FCF Margin stood at 4985.56% in 2022, then plunged by 44 bps to 7177.88% in 2023, then soared by 54 bps to 3321.54% in 2024, then jumped by 99 bps to 37.3% in 2025, then tumbled by 172 bps to 101.46% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 101.46%, 37.3%, and 90.3% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.17% |
| 10 | BridgeBio Pharma | 12.91 Bn | 11.98 Bn | 184.58 Mn | -101.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -101.46% |
| Dec 31, 2025 | -37.30% |
| Sep 30, 2025 | -90.30% |
| Jun 30, 2025 | -73.20% |
| Mar 31, 2025 | -171.11% |
| Dec 31, 2024 | -3,321.54% |
| Sep 30, 2024 | -6,639.17% |
| Jun 30, 2024 | 3,445.71% |
| Mar 31, 2024 | -104.02% |
| Dec 31, 2023 | -7,177.88% |
| Sep 30, 2023 | -3,567.98% |
| Jun 30, 2023 | -6,914.81% |
| Mar 31, 2023 | -7,904.38% |
| Dec 31, 2022 | -4,985.56% |
| Sep 30, 2022 | -39,985.21% |
| Jun 30, 2022 | -40.23% |
| Mar 31, 2022 | -9,533.29% |
| Dec 31, 2021 | -1,364.31% |
| Sep 30, 2021 | -5,461.73% |
| Jun 30, 2021 | -1,105.88% |
| Mar 31, 2021 | -33,057.58% |
| Dec 31, 2020 | -75,401.64% |
| Sep 30, 2020 | -1,627.08% |
| Sep 30, 2019 | -188.68% |